Ritodrine
As of the edition of 20 October 2026, Ritodrine is a small molecule: marketed, first approved in 1973 (ES); acts on ADRB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Yutopar
- First approved
- 1 May 1973 (ES)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- AstraZeneca; 2 holders in all
- Registered trials
- 2, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Acquired holder | 2003 to now |
| Astra | Earlier holder |